Prosonix' proprietary particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products. Prosonix' pipeline focuses on near- and long-term opportunities, and is further complemented by a select number of partnered respiratory programmes. The in-house pipeline includes: Additional partnered respiratory programmes include: Global Initiative for Asthma (GINA) Guidelines - Updated July 2014 Evohaler® Flixotide®, Flovent®, Seretide® and Serevent® are trademarks of the GlaxoSmithKline group of companies. Spiriva® is a trademark of Boehringer Ingelheim.